NCT04646603View on ClinicalTrials.gov

MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients

PHASE2UnknownINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

March 31, 2022

Study Completion Date

July 1, 2022

Conditions
COVID-19ARDS, HumanStem CellsRegeneration
Interventions
DRUG

MRG-001

Subjects will receive subcutaneous MRG-001 injections.

DRUG

Placebo

Subjects will receive subcutaneous placebo injections.

Trial Locations (1)

21205

RECRUITING

Johns Hopkins Medicine, Baltimore

Sponsors

Lead Sponsor

MedRegen LLC

Collaborators (1)

ICON plc
All Listed Sponsors
collaborator

ICON plc

INDUSTRY

collaborator

Johns Hopkins University

OTHER

lead

MedRegen LLC

INDUSTRY

NCT04646603 - MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients | Biotech Hunter | Biotech Hunter